Development of a novel and highly selective CDK4/6 inhibitor for treating cancer

开发用于治疗癌症的新型高选择性 CDK4/6 抑制剂

• 批准号: nhmrc : 1135682
• 负责人: A/Pr Elgene Lim
• 金额: $ 79.19万
• 依托单位: University of South Australia
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-novel-highly-treating-cancer/1318258
• 关键词: Development; novel; highly; selective; CDK4

We have identified and patented novel drug molecules targeting enzymes namely CDKs 4 and 6, that are important for survival of cancer cells. The drugs are highly selective and potent against CDK4/6, well absorbed orally, and have attracted much interest from a pharmaceutical company. Further detailed work is needed to characterize fully their anti-cancer effects and toxicity, thereby securing a major investment from our commercial partner for drug development for treating cancers.

我们已经确定了针对酶（即 CDK 4 和 6）的新型药物分子并获得了专利，这对癌细胞的生存很重要。该药物对CDK4/6具有高选择性和强效性，口服吸收良好，引起了制药公司的浓厚兴趣。需要进一步详细的工作来充分表征其抗癌作用和毒性，从而确保我们的商业合作伙伴对治疗癌症的药物开发进行重大投资。